Regulatory surveillance over supply chain of weight-loss drug GLP-1 intensified

NEW DELHI: (Mar 24) To ensure ethical pharmaceutical practices in the supply chain of weight-loss drugs of the GLP-1 class, the Drugs Controller General of India (DCGI) has intensified its regulatory surveillance against the unauthorised sale and promotion of the medications.

To this end, inspections and audits have been carried out at many online pharmacy warehouses, drug wholesalers and retailers to check for unauthorised sale and improper prescription.

With the recent introduction of multiple generic variants of GLP-1-based weight-loss drugs in the Indian market, concerns have emerged regarding their on-demand availability through retail pharmacies, online platforms, wholesalers, and wellness clinics, health ministry officials said on Tuesday.